If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks ...

Pfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...

Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...

Indian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acqu...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Pfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...

Biocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...

In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...

Amazon Web Services has launched Amazon Bio Discovery, an AI tool to accelerate drug discovery. Scientists can now generate and evaluate po...

Aurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...

Gilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...

Merck is acquiring Terns Pharma for $6.7 billion to strengthen its cancer drug pipeline, aiming to reduce reliance on its blockbuster Keytr...

Swiss drugmaker Novartis is set to acquire a promising breast cancer drug candidate from US biotech firm Synnovation Therapeutics. The deal...

Merck KGaA is betting on its oncology pipeline to revitalise the German drugmaker as it sees falling sales from its best-selling medicine, ...

Britain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.

New and considerable optimism over cancer drugs will drive deal-making in pharma over the decade, with companies weak in this segment tryin...